Total amount: € 0,00
Official Journal of the Italian Society of Dermatology and Sexually Transmitted Diseases
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,014
Online ISSN 1827-1820
Pincelli C., Giannetti A.
Department of Dermatology, University of Modena and Reggio Emilia, Modena, Italy
Severe psoriasis is a chronic and disabling disease. One quarter of these patients require systemic therapy to control their condition properly. However, these therapies are limited by toxic effects and by the need of extensive laboratory monitoring. The improved knowledge of the pathogenesis of psoriasis has impelled the development of selective biological therapies with an excellent risk/benefit profile that has made it possible to treat psoriatic patients for long periods of time. At present, however, it is not possible to determine which biologic agent is the best because the lack of head-to-head trials and because psoriasis is not just one disease and not all psoriatic patients are the same. While patients treated with anti-TNFα drugs seem to have a fast and good response in the short period and in patients with PsA, their efficacy seem to decrease in the long term with possible increased risk of adverse events. On the other hand, efalizumab has a lower PASI-75 at 3 months, but it is currently the only biologic agent with more than 3-years data set with a maintained or improved PASI-75 without increased rate of adverse events.